Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa

뉴스 본문을 불러오고 있어요.

Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa | 웨이프 WAPE

Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa

기사 요약

관련 종목

댓글 —